vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and InvenTrust Properties Corp. (IVT). Click either name above to swap in a different company.

InvenTrust Properties Corp. is the larger business by last-quarter revenue ($77.4M vs $45.1M, roughly 1.7× Amarin Corp plc). InvenTrust Properties Corp. runs the higher net margin — 3.4% vs -23.3%, a 26.7% gap on every dollar of revenue. On growth, InvenTrust Properties Corp. posted the faster year-over-year revenue change (8.6% vs 7.0%). Over the past eight quarters, InvenTrust Properties Corp.'s revenue compounded faster (7.6% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

InvenTrust Properties Corp. is a real estate investment trust that invests in shopping malls. As of December 31, 2024, the company owned interests in 68 properties comprising 11.0 million square feet.

AMRN vs IVT — Head-to-Head

Bigger by revenue
IVT
IVT
1.7× larger
IVT
$77.4M
$45.1M
AMRN
Growing faster (revenue YoY)
IVT
IVT
+1.6% gap
IVT
8.6%
7.0%
AMRN
Higher net margin
IVT
IVT
26.7% more per $
IVT
3.4%
-23.3%
AMRN
Faster 2-yr revenue CAGR
IVT
IVT
Annualised
IVT
7.6%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
IVT
IVT
Revenue
$45.1M
$77.4M
Net Profit
$-10.5M
$2.7M
Gross Margin
Operating Margin
35.5%
-11.0%
Net Margin
-23.3%
3.4%
Revenue YoY
7.0%
8.6%
Net Profit YoY
33.0%
-72.8%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
IVT
IVT
Q1 26
$45.1M
Q4 25
$49.2M
$77.4M
Q3 25
$49.7M
$74.5M
Q2 25
$72.7M
$73.6M
Q1 25
$42.0M
$73.8M
Q4 24
$62.3M
$71.2M
Q3 24
$42.3M
$68.5M
Q2 24
$67.5M
$67.4M
Net Profit
AMRN
AMRN
IVT
IVT
Q1 26
$-10.5M
Q4 25
$-1.2M
$2.7M
Q3 25
$-7.7M
$6.0M
Q2 25
$-14.1M
$95.9M
Q1 25
$-15.7M
$6.8M
Q4 24
$-48.6M
$9.8M
Q3 24
$-25.1M
$-539.0K
Q2 24
$1.5M
$1.5M
Gross Margin
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
Q2 24
63.4%
Operating Margin
AMRN
AMRN
IVT
IVT
Q1 26
35.5%
Q4 25
-12.9%
-11.0%
Q3 25
-22.4%
-9.8%
Q2 25
-22.0%
Q1 25
-39.9%
-10.5%
Q4 24
-84.3%
-3.6%
Q3 24
-59.5%
-18.7%
Q2 24
-0.8%
-13.6%
Net Margin
AMRN
AMRN
IVT
IVT
Q1 26
-23.3%
Q4 25
-2.5%
3.4%
Q3 25
-15.6%
8.1%
Q2 25
-19.4%
130.4%
Q1 25
-37.4%
9.2%
Q4 24
-78.0%
13.8%
Q3 24
-59.4%
-0.8%
Q2 24
2.3%
2.2%
EPS (diluted)
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
$0.00
$0.02
Q3 25
$-0.02
$0.08
Q2 25
$-0.03
$1.23
Q1 25
$-0.04
$0.09
Q4 24
$-0.12
$0.14
Q3 24
$-0.06
$-0.01
Q2 24
$0.00
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
IVT
IVT
Cash + ST InvestmentsLiquidity on hand
$307.8M
Total DebtLower is stronger
$825.9M
Stockholders' EquityBook value
$1.8B
Total Assets
$645.8M
$2.8B
Debt / EquityLower = less leverage
0.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
IVT
IVT
Q1 26
$307.8M
Q4 25
$302.6M
Q3 25
$286.6M
Q2 25
$298.7M
Q1 25
$281.8M
Q4 24
$294.2M
Q3 24
$305.7M
Q2 24
$306.7M
Total Debt
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
$825.9M
Q3 25
$764.6M
Q2 25
$746.3M
Q1 25
$740.7M
Q4 24
$740.4M
Q3 24
$740.1M
Q2 24
$812.2M
Stockholders' Equity
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
$459.3M
$1.8B
Q3 25
$458.9M
$1.8B
Q2 25
$464.9M
$1.8B
Q1 25
$473.7M
$1.7B
Q4 24
$486.2M
$1.8B
Q3 24
$531.4M
$1.8B
Q2 24
$551.9M
$1.5B
Total Assets
AMRN
AMRN
IVT
IVT
Q1 26
$645.8M
Q4 25
$670.8M
$2.8B
Q3 25
$659.8M
$2.7B
Q2 25
$670.1M
$2.7B
Q1 25
$655.7M
$2.6B
Q4 24
$685.3M
$2.6B
Q3 24
$750.6M
$2.6B
Q2 24
$799.9M
$2.5B
Debt / Equity
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
0.46×
Q3 25
0.42×
Q2 25
0.41×
Q1 25
0.42×
Q4 24
0.42×
Q3 24
0.42×
Q2 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
IVT
IVT
Operating Cash FlowLast quarter
$155.4M
Free Cash FlowOCF − Capex
$110.9M
FCF MarginFCF / Revenue
143.3%
Capex IntensityCapex / Revenue
57.5%
Cash ConversionOCF / Net Profit
58.41×
TTM Free Cash FlowTrailing 4 quarters
$193.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
$15.3M
$155.4M
Q3 25
$-12.7M
$43.8M
Q2 25
$16.6M
$48.7M
Q1 25
$-12.5M
$20.2M
Q4 24
$-13.3M
$136.9M
Q3 24
$-2.4M
$38.4M
Q2 24
$-2.7M
$46.7M
Free Cash Flow
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
$110.9M
Q3 25
$31.4M
Q2 25
$38.0M
Q1 25
$12.8M
Q4 24
$100.8M
Q3 24
$29.3M
Q2 24
$37.2M
FCF Margin
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
143.3%
Q3 25
42.2%
Q2 25
51.6%
Q1 25
17.4%
Q4 24
141.5%
Q3 24
42.8%
Q2 24
55.2%
Capex Intensity
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
57.5%
Q3 25
16.7%
Q2 25
14.6%
Q1 25
10.0%
Q4 24
50.7%
Q3 24
13.3%
Q2 24
14.0%
Cash Conversion
AMRN
AMRN
IVT
IVT
Q1 26
Q4 25
58.41×
Q3 25
7.27×
Q2 25
0.51×
Q1 25
2.97×
Q4 24
13.97×
Q3 24
Q2 24
-1.81×
31.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

IVT
IVT

Segment breakdown not available.

Related Comparisons